Resiquimod Active Not Recruiting Phase 2 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00960752Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist